Osteoporosis

You have full text access to this OnlineOpen article

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six–month results of a randomized, double-blind, controlled trial†

  1. Kenneth G. Saag1,‡,*,
  2. Jose R. Zanchetta2,§,
  3. Jean-Pierre Devogelaer3,¶,
  4. Robert A. Adler4,‖,
  5. Richard Eastell5,††,
  6. Kyoungah See6,‡‡,
  7. John H. Krege6,‡‡,
  8. Kelly Krohn6,‡‡,
  9. Margaret R. Warner6,‡‡

Article first published online: 29 OCT 2009

DOI: 10.1002/art.24879

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 60, Issue 11, pages 3346–3355, November 2009

Additional Information

How to Cite

Saag, K. G., Zanchetta, J. R., Devogelaer, J.-P., Adler, R. A., Eastell, R., See, K., Krege, J. H., Krohn, K. and Warner, M. R. (2009), Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six–month results of a randomized, double-blind, controlled trial. Arthritis & Rheumatism, 60: 3346–3355. doi: 10.1002/art.24879

Author Information

  1. 1

    University of Alabama at Birmingham

  2. 2

    Universidad del Salvador, Buenos Aires, Argentina

  3. 3

    Université Catholique de Louvain, Brussels, Belgium

  4. 4

    McGuire VAMC, Richmond, Virginia

  5. 5

    University of Sheffield, Sheffield, UK

  6. 6

    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana

  1. ‡

    Dr. Saag has received consulting and speaking fees from Novartis (more than $10,000) and from Eli Lilly, Merck, Amgen, Procter & Gamble, and Aventis (less than $10,000 each).

  2. §

    Dr. Zanchetta has received consulting and speaking fees from Amgen, Eli Lilly, Pfizer, and Servier (less than $10,000 each).

  3. Dr. Devogelaer receives research support from Amgen, Eli Lilly, Merck, Nordic Bioscience, Novartis, Pfizer, Procter & Gamble, Sanofi-Aventis, Servier, and Wyeth and speaking fees from Eli Lilly, Novartis, Procter & Gamble, and Servier (less than $10,000 each).

  4. ‖

    Dr. Adler has received speaking and consulting fees from Eli Lilly, Novartis, and Merck (less than $10,000 each), and research support from Eli Lilly, Novartis, and Procter & Gamble.

  5. ††

    Dr. Eastell has received consulting or advisory board fees from Amgen, Novartis, Procter & Gamble, Servier, Ono, and GlaxoSmithKline (less than $10,000 each), lecture fees from Eli Lilly (less than $10,000), and grant support from AstraZeneca, Procter & Gamble, and Novartis (less than $10,000 each).

  6. ‡‡

    Drs. See, Krege, Krohn, and Warner own stock or stock options in Eli Lilly.

*University of Alabama at Birmingham, FOT 820, 1530 Third Avenue South, Birmingham, AL 35294-3408

  1. †

    ClinicalTrials.gov identifier: NCT00051558.

Publication History

  1. Issue published online: 29 OCT 2009
  2. Article first published online: 29 OCT 2009
  3. Manuscript Accepted: 11 JUL 2009
  4. Manuscript Received: 12 DEC 2008

Funded by

  • Eli Lilly and Company

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (125K)

REFERENCES

  • 1
    American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001; 44: 1496–503.
    Direct Link:
  • 2
    Saag KG. Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am 2003; 32: 135–57.
  • 3
    Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007; 18: 1319–28.
  • 4
    Rubin MR, Bilezikian JP. Clinical review 151—the role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab 2002; 87: 4033–41.
  • 5
    Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15: 993–1000.
    Direct Link:
  • 6
    Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003; 48: 3224–9.
    Direct Link:
  • 7
    Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton LJ III, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19: 893–9.
    Direct Link:
  • 8
    Royal College of Physicians. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. URL: www.rcplondon.ac.uk/pubs/books/glucocorticoid/index.asp.
  • 9
    Devogelaer JP, Goemaere S, Boonen S, Body JJ, Kaufman JM, Reginster JY, et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 2006; 17: 8–19.
  • 10
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434–41.
  • 11
    Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, et al. The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18: 9–17.
    Direct Link:
  • 12
    Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003; 18: 1932–41.
    Direct Link:
  • 13
    Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007; 357: 905–16.
  • 14
    Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995; 136: 3632–8.
  • 15
    Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999; 104: 439–46.
  • 16
    Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: results of a randomized controlled clinical trial. J Clin Invest 1998; 102: 1627–33.
  • 17
    Rehman Q, Lang TF, Arnaud CD, Modin GW, Lane NE. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2003; 14: 77–81.
  • 18
    Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357: 2028–39.
  • 19
    Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993; 8: 1137–48.
    Direct Link:
  • 20
    Westfall PH, Krishen A. Optimally weighted, fixed sequence, and gatekeeping multiple testing procedures. J Stat Plan Inference 2001; 99: 25–40.
  • 21
    Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve month, multicenter, randomized, double-blind, placebo-controlled parallel-group study. Arthritis Rheum 1999; 42: 2309–18.
    Direct Link:
  • 22
    Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339: 292–9.
  • 23
    Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44: 202–11.
    Direct Link:
  • 24
    Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000; 15: 1006–13.
    Direct Link:
  • 25
    Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003; 14: 801–7.
  • 26
    Szulc P, Delmas PD. Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int 2008; 19: 1683–704.
  • 27
    McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005; 165: 1762–8.
  • 28
    Rubin MR, Bilezikian JP. The anabolic effects of parathyroid hormone therapy. Clin Geriatr Med 2003; 19: 415–32.
  • 29
    Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001; 16: 1846–53.
    Direct Link:
  • 30
    Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000; 85: 4118–24.
  • 31
    Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437–43.
  • 32
    McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 2008; 20: 131–7.
  • 33
    Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999; 14: 1061–6.
    Direct Link:
View Full Article (HTML) Get PDF (125K)